Elliot Wilbur
Stock Analyst at Raymond James
(1.95)
# 3,072
Out of 5,170 analysts
55
Total ratings
33.33%
Success rate
5.35%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $25 → $32 | $15.02 | +113.05% | 8 | May 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $74.82 | +10.93% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $60 → $40 | $81.71 | -51.05% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $6.27 | +426.32% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $9.65 | +345.60% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $4.37 | +2,646.00% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $13.50 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $29.44 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $115.99 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $25.12 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $6.95 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.54 | - | 3 | Nov 9, 2017 |
ADMA Biologics
May 8, 2025
Maintains: Strong Buy
Price Target: $25 → $32
Current: $15.02
Upside: +113.05%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $74.82
Upside: +10.93%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $60 → $40
Current: $81.71
Upside: -51.05%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $6.27
Upside: +426.32%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $9.65
Upside: +345.60%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $4.37
Upside: +2,646.00%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $13.50
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $29.44
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $115.99
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $25.12
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $6.95
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $19.54
Upside: -